Literature DB >> 22095129

Pre-steady-state kinetics of interaction of wild-type and multiple drug-resistant HIV protease with first and second generation inhibitory drugs.

N A Kuznetsov1, A V Kozyr, M A Dronina, I V Smirnov, E N Kaliberda, A G Mikhailova, L D Rumsh, O S Fedorova, A G Gabibov, A V Kolesnikov.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22095129     DOI： 10.1134/S1607672911050139

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  15 in total

1.  HIV-1 protease: characterization of a catalytically competent enzyme-substrate intermediate.

Authors:  David J T Porter; Mary H Hanlon; Eric S Furfine
Journal:  Biochemistry       Date:  2002-01-29       Impact factor: 3.162

2.  Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.

Authors:  Nevra Ozer; Celia A Schiffer; Turkan Haliloglu
Journal:  Biophys J       Date:  2010-09-08       Impact factor: 4.033

Review 3.  Recent advances in antiretroviral drugs.

Authors:  Raktim Kumar Ghosh; Samhati Mondal Ghosh; Shalini Chawla
Journal:  Expert Opin Pharmacother       Date:  2010-08-10       Impact factor: 3.889

Review 4.  From HIV to tuberculosis and back again: a tale of activism in 2 pandemics.

Authors:  Mark Harrington
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

5.  Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Authors:  Manabu Aoki; David J Venzon; Yasuhiro Koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 6.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

Review 7.  New insights into small-molecule inhibitors of Bcr-Abl.

Authors:  S Schenone; O Bruno; M Radi; M Botta
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

8.  Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Pavlína Rezácová; Jirí Brynda; Tatyana Yashina; Ron M Kagan; Jan Konvalinka
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

Review 9.  HIV therapy advances. Update on a proteinase inhibitor.

Authors:  S Vella
Journal:  AIDS       Date:  1994-09       Impact factor: 4.177

10.  The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties.

Authors:  A M Mildner; D J Rothrock; J W Leone; C A Bannow; J M Lull; I M Reardon; J L Sarcich; W J Howe; C S Tomich; C W Smith
Journal:  Biochemistry       Date:  1994-08-16       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.